Personalized Therapy: Can it Tame the COVID-19 Monster?

References

• COVID-19 Map – Johns Hopkins Coronavirus Resource Center (2021). https://coronavirus.jhu.edu/map.html
   Google Scholar
• Hacisuleyman E , HaleC , SaitoYet al. Vaccine breakthrough infections with SARS-CoV-2 variants. N. Engl. J. Med.384(23), 2212–2218 (2021).
   PubMed Web of Science ®Google Scholar
• Blanco-Melo D , Nilsson-PayantBE , LiuW-Cet al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell181(5), 1035–1049.e9 (2020).
   Web of Science ®Google Scholar
• Stebbing J , PhelanA , GriffinIet al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect. Dis.20(4), 400–402 (2020).
   PubMed Web of Science ®Google Scholar
• Naz F , ArishM. Battling COVID-19 pandemic: sphingosine-1-phosphate analogs as an adjunctive therapy?Front. Immunol.11, 1102 (2020).
   PubMed Web of Science ®Google Scholar
• Wang M , CaoR , ZhangLet al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res.30, 269–271 (2020).
   PubMed Web of Science ®Google Scholar
• Chen Z , HuJ , ZhangZet al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv doi:10.1101/2020.03.22.20040758 (2020) ( Epub ahead of print).
   Google Scholar
• Gautret P , LagierJ-C , ParolaPet al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med. Infect. Dis.34, 101663 (2020).
   PubMed Web of Science ®Google Scholar
• Grein J , OhmagariN , ShinDet al. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med.382(24), 2327–2336 (2020).
   PubMed Web of Science ®Google Scholar
• Wang Y , ZhangD , DuGet al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet395(10236), 1569–1578 (2020).
   PubMed Web of Science ®Google Scholar
• Cao B , WangY , WenDet al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med.382(19), 1787–1799 (2020).
   PubMed Web of Science ®Google Scholar
• Chen C , HuangJ , ChengZet al. Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial. Front. Pharmacol.12, 2292 (2020).
   Web of Science ®Google Scholar
• Russell CD , MillarJE , BaillieJK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet395(10223), 473–475 (2020).
   PubMed Web of Science ®Google Scholar
• Cano EJ , FonsecaFuentes X , CorsiniCampioli Cet al. Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta-analysis. Chest159(3), 1019–1040 (2021).
   PubMed Web of Science ®Google Scholar
• Zha L , LiS , PanLet al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med. J. Aust.212(9), 416–420 (2020).
   PubMed Web of Science ®Google Scholar
• Vincent MJ , BergeronE , BenjannetSet al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J.2, 69 (2005).
   PubMed Web of Science ®Google Scholar
• Liu J , CaoR , XuMet al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov.6(1), 16 (2020).
   PubMed Web of Science ®Google Scholar
• Gautret P , LagierJ-C , ParolaPet al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int. J. Antimicrob. Agents56(1), 105949 (2020).
   PubMed Web of Science ®Google Scholar
• Geleris J , SunY , PlattJet al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N. Engl. J. Med.382(25), 2411–2418 (2020).
   PubMed Web of Science ®Google Scholar
• Sanders JM , MonogueML , JodlowskiTZ , CutrellJB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA323(18), 1824–1836 (2020).
   PubMed Web of Science ®Google Scholar
• Gordon CJ , TchesnokovEP , FengJY , PorterDP , GotteM. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J. Biol. Chem.295(15), 4773–4779 (2020).
   PubMed Web of Science ®Google Scholar
• Frediansyah A , NainuF , DhamaK , MudatsirM , HarapanH. Remdesivir and its antiviral activity against COVID-19: a systematic review. Clin. Epidemiol. Glob. Health9, 123–127 (2021).
   PubMed Web of Science ®Google Scholar
• Chandwani A , ShuterJ. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther. Clin. Risk Manag.4(5), 1023–1033 (2008).
   PubMedGoogle Scholar
• Zhu Z , LuZ , XuTet al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J. Infect.81(1), e21–e23 (2020).
   PubMed Web of Science ®Google Scholar
• Delang L , AbdelnabiR , NeytsJ. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res.153, 85–94 (2018).
   PubMed Web of Science ®Google Scholar
• Huang C , WangY , LiXet al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet395(10223), 497–506 (2020).
   PubMed Web of Science ®Google Scholar
• Chen N , ZhouM , DongXet al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet395(10223), 507–513 (2020).
   PubMed Web of Science ®Google Scholar
• Gogali A , KyriakopoulosC , KostikasK. Corticosteroids in COVID-19: one size does not fit all, European Respiratory Society. Eur. Respir. J.57(4), 2100224 (2021).
   PubMedGoogle Scholar
• Yang Z , LiuJ , ZhouY , ZhaoX , ZhaoQ , LiuJ. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J. Infect.81(1), e13–e20 (2020).
   PubMed Web of Science ®Google Scholar
• Casadevall A , PirofskiL. The convalescent sera option for containing COVID-19. J. Clin. Invest.130(4), 1545–1548 (2020).
   PubMed Web of Science ®Google Scholar
• Cheng Y , WongR , SooYOYet al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur. J. Clin. Microbiol. Infect. Dis.24(1), 44–46 (2005).
   PubMed Web of Science ®Google Scholar
• Ko JH , SeokH , ChoSYet al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir. Ther.23(7), 617–622 (2018).
   PubMed Web of Science ®Google Scholar
• Chen L , XiongJ , BaoL , ShiY. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis.20(4), 398–400 (2020).
   PubMed Web of Science ®Google Scholar
• Luke TC , KilbaneEM , JacksonJL , HoffmanSL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: A future H5N1 treatment?Ann. Intern. Med.145(8), 599–609 (2006).
   PubMed Web of Science ®Google Scholar
• Shen C , WangZ , ZhaoFet al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA323(16), 1582–1589 (2020).
   PubMed Web of Science ®Google Scholar
• Duan K , LiuB , LiCet al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc. Natl Acad. Sci. USA117(17), 9490–9496 (2020).
   PubMed Web of Science ®Google Scholar
• Liu L , WeiQ , LinQet al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight4(4), e123158 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang L , ZhangF , YuWet al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J. Med. Virol.78(1), 1–8 (2006).
   PubMed Web of Science ®Google Scholar
• Li L , ZhangW , HuYet al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA324(5), 460–470 (2020).
   PubMed Web of Science ®Google Scholar
• Simonovich VA , BurgosPratx LD , ScibonaPet al. A randomized trial of convalescent plasma in COVID-19 severe pneumonia. N. Engl. J. Med.384(7), 619–629 (2021).
   PubMed Web of Science ®Google Scholar
• Zhou F , YuT , DuRet al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet395(10229), 1054–1062 (2020).
   PubMed Web of Science ®Google Scholar
• Chen G , WuD , GuoWet al. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. J. Clin. Invest.130(5), 2620–2629 (2020).
   PubMed Web of Science ®Google Scholar
• Wang C , FeiD , LiX , ZhaoM , YuK. IL-6 may be a good biomarker for earlier detection of COVID-19 progression. Intensive Care Med.46(7), 1475–1476 (2020).
   PubMed Web of Science ®Google Scholar
• Liu B , LiM , ZhouZ , GuanX , XiangY. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?J. Autoimmun.111, 102452 (2020).
   PubMed Web of Science ®Google Scholar
• Kaly L , RosnerI. Tocilizumab – a novel therapy for non-organ-specific autoimmune diseases. Best Pract. Res. Clin. Rheumatol.26(1), 157–165 (2012).
   PubMed Web of Science ®Google Scholar
• Luo P , LiuY , QiuL , LiuX , LiuD , LiJ. Tocilizumab treatment in COVID-19: a single center experience. J. Med. Virol.92(7), 814–818 (2020).
   PubMed Web of Science ®Google Scholar
• Alattar R , IbrahimTBH , ShaarSHet al. Tocilizumab for the treatment of severe coronavirus disease 2019. J. Med. Virol.92(10), 2042–2049 (2020).
   PubMed Web of Science ®Google Scholar
• Xu X , HanM , LiTet al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl Acad. Sci. USA117(20), 10970–10975 (2020).
   PubMed Web of Science ®Google Scholar
• Abani O , AbbasA , AbbasFet al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet397(10285), 1637–1645 (2021).
   PubMed Web of Science ®Google Scholar
• Rosas IO , BråuN , WatersMet al. Tocilizumab in hospitalized patients with severe COVID-19 pneumonia. N. Engl. J. Med.384(16), 1503–1516 (2021).
   PubMed Web of Science ®Google Scholar
• Wagstaff KM , SivakumaranH , HeatonSM , HarrichD , JansDA. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochem. J.443(3), 851–856 (2012).
   PubMed Web of Science ®Google Scholar
• Caly L , DruceJD , CattonMG , JansDA , WagstaffKM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res.178, 104787 (2020).
   PubMed Web of Science ®Google Scholar
• Krolewiecki A , LifschitzA , MoragasMet al. Antiviral effect of high-dose ivermectin in adults with COVID-19: a proof-of-concept randomized trial. EClin. Med.37, 100959 (2021).
   PubMedGoogle Scholar
• Chaccour C , CasellasA , Blanco-DiMatteo Aet al. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial. EClin. Med.32, 100720 (2021).
   PubMedGoogle Scholar
• Xia S , LiuM , WangCet al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res.30(4), 343–355 (2020).
   PubMed Web of Science ®Google Scholar
• Richardson P , GriffinI , TuckerCet al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet395(10223), e30–e31 (2020).
   PubMed Web of Science ®Google Scholar
• Favalli EG , BiggioggeroM , MaioliG , CaporaliR. Baricitinib for COVID-19: a suitable treatment?Lancet Infect. Dis.20(9), 1012–1013 (2020).
   PubMed Web of Science ®Google Scholar
• Kalil AC , PattersonTF , MehtaAKet al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N. Engl. J. Med.384(9), 795–807 (2021).
   PubMed Web of Science ®Google Scholar
• Walensky RP , WalkeHT , FauciAS. SARS-CoV-2 variants of concern in the United States-challenges and opportunities. JAMA325(11), 1037–1038 (2021).
   PubMed Web of Science ®Google Scholar
• Harvey WT , CarabelliAM , JacksonBet al. SARS-CoV-2 variants, spike mutations and immune escape. Nature Rev. Microbiol.19(7), 409–424 (2021).
   PubMed Web of Science ®Google Scholar
• Brodin P . Immune determinants of COVID-19 disease presentation and severity. Nature Med.27(1), 28–33 (2021).
   PubMed Web of Science ®Google Scholar
• Jørgensen SE , ChristiansenM , RyøLBet al. Defective RNA sensing by RIG-I in severe influenza virus infection. Clin. Exp. Immunol.192(3), 366–376 (2018).
   PubMed Web of Science ®Google Scholar
• Yamada T , SatoS , SotoyamaYet al. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat. Immunol.22(7), 820–828 (2021).
   PubMed Web of Science ®Google Scholar
• Pothlichet J , NiewoldTB , VitourD , SolhonneB , CrowMK , Si-TaharM. A loss-of-function variant of the antiviral molecule MAVS is associated with a subset of systemic lupus patients. EMBO Mol. Med.3(3), 142–152 (2011).
   PubMed Web of Science ®Google Scholar
• Ulhaq ZS , SorayaGV. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia. Med. Clin.155(12), 548–556 (2020).
   PubMed Web of Science ®Google Scholar
• Badary OA . Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs. Pharmacogenomics J.21(3), 275–284 (2021).
   PubMed Web of Science ®Google Scholar
• Lee JY , VinayagamoorthyN , HanKet al. Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus. Arthritis Rheumatol.68(1), 184–190 (2016).
   PubMed Web of Science ®Google Scholar
• Elens L , YombiJC , LisonD , WallemacqP , VandercamB , HaufroidV. Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics10(10), 1589–1597 (2009).
   PubMed Web of Science ®Google Scholar
• Zhou A , SabatelloM , EyalGet al. Is precision medicine relevant in the age of COVID-19? Genet. Med. 23(6), 999–1000 (2021).
   PubMed Web of Science ®Google Scholar
• Demerle K , AngusDC , SeymourCW. Precision medicine for COVID-19: phenotype anarchy or promise realized?JAMA325(20), 2041–2042 (2021).
   PubMed Web of Science ®Google Scholar
• Wan S , YiQ , FanSet al. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients. Br. J. Haematol.189(3), 428–437 (2020).
   PubMed Web of Science ®Google Scholar
• Luft T , WendtnerC-M , KoselyFet al. EASIX for prediction of outcome in hospitalized SARS-CoV-2 infected patients. Front. Immunol.12, 1 (2021).
   Web of Science ®Google Scholar
• Garcia-Vidal C , Moreno-GarcíaE , Hernández-MenesesMet al. Personalized therapy approach for hospitalized patients with COVID-19. Clin. Infect. Dis.ciaa964 (2020).
   Web of Science ®Google Scholar
• Mehta P , McAuleyDF , BrownM , SanchezE , TattersallRS , MansonJJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet395(20229), 1033–1034 (2020).
   PubMedGoogle Scholar
• Lauring AS , HodcroftEB. Genetic variants of SARS-CoV-2 – what do they mean?JAMA325(6), 529–531 (2021).
   PubMed Web of Science ®Google Scholar
• Santus E , MarinoN , CirilloDet al. Artificial intelligence-aided precision medicine for COVID-19: strategic areas of research and development. J. Med. Internet Res.23(3), e22453 (2021).
   PubMed Web of Science ®Google Scholar
• Smith PF , DoddsM , BentleyD , YeoK , RaynerC. Dosing will be a key success factor in repurposing antivirals for COVID-19. Br. J. Clin. Pharmacol.87(9), 3451–3454 (2020).
   PubMed Web of Science ®Google Scholar
• Adam G , RampášekL , SafikhaniZ , SmirnovP , Haibe-KainsB , GoldenbergA. Machine learning approaches to drug response prediction: challenges and recent progress. NPJ Precis. Oncol.4, 19 (2020).
   PubMed Web of Science ®Google Scholar